I-Mab (IMAB) Competitors $5.09 +0.38 (+8.07%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.12 +0.04 (+0.69%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB vs. WVE, JANX, EWTX, ARDX, HROW, SPRY, SDGR, AMPH, VERA, and ABCLShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Its Competitors WAVE Life Sciences Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics I-Mab (NASDAQ:IMAB) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability. Do analysts recommend IMAB or WVE? I-Mab presently has a consensus target price of $6.50, suggesting a potential upside of 27.70%. WAVE Life Sciences has a consensus target price of $20.27, suggesting a potential upside of 99.67%. Given WAVE Life Sciences' higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than I-Mab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33WAVE Life Sciences 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more volatility & risk, IMAB or WVE? I-Mab has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500. Does the media refer more to IMAB or WVE? In the previous week, I-Mab had 18 more articles in the media than WAVE Life Sciences. MarketBeat recorded 21 mentions for I-Mab and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.30 beat I-Mab's score of 0.79 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, IMAB or WVE? I-Mab has higher earnings, but lower revenue than WAVE Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-Mab$3.89M106.85-$22.23MN/AN/AWAVE Life Sciences$108.30M14.91-$97.01M-$0.90-11.28 Is IMAB or WVE more profitable? I-Mab's return on equity of -19.65% beat WAVE Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A -19.65% -18.58% WAVE Life Sciences N/A -78.45%-41.51% Do insiders & institutionals hold more shares of IMAB or WVE? 38.4% of I-Mab shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 24.0% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryI-Mab beats WAVE Life Sciences on 8 of the 14 factors compared between the two stocks. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$415.65M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E RatioN/A21.0031.3626.05Price / Sales106.85209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book2.118.129.536.60Net Income-$22.23M-$54.72M$3.26B$265.65M7 Day Performance4.52%2.62%2.14%2.00%1 Month Performance140.09%3.25%3.22%0.46%1 Year Performance318.93%10.82%30.18%18.88% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab3.306 of 5 stars$5.09+8.1%$6.50+27.7%+318.9%$415.65M$3.89M0.00380News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionWVEWAVE Life Sciences4.7597 of 5 stars$9.74-0.2%$20.27+108.1%+76.8%$1.55B$108.30M-10.82240Positive NewsJANXJanux Therapeutics2.1448 of 5 stars$25.53+1.7%$91.89+259.9%-47.1%$1.51B$10.59M-14.1830News CoverageEWTXEdgewise Therapeutics2.3903 of 5 stars$14.00-1.1%$41.60+197.1%-23.2%$1.49BN/A-9.0360News CoverageAnalyst ForecastARDXArdelyx4.3096 of 5 stars$5.81-2.7%$11.50+97.9%-3.8%$1.44B$386.15M-25.2690Positive NewsHROWHarrow3.6201 of 5 stars$38.32-1.3%$64.67+68.8%-8.4%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4582 of 5 stars$14.03-3.4%$31.00+121.0%+4.2%$1.44B$89.15M-28.6390News CoverageInsider TradeSDGRSchrodinger3.0975 of 5 stars$20.05+3.5%$27.83+38.8%+2.3%$1.43B$207.54M-8.08790AMPHAmphastar Pharmaceuticals3.4582 of 5 stars$29.76-0.2%$31.50+5.8%-36.4%$1.39B$731.97M11.152,028VERAVera Therapeutics3.7276 of 5 stars$21.80+1.2%$63.00+189.0%-42.6%$1.37BN/A-6.0940News CoveragePositive NewsABCLAbCellera Biologics2.0891 of 5 stars$4.67+1.7%$8.00+71.3%+68.2%$1.37B$28.83M-8.49500 Related Companies and Tools Related Companies WAVE Life Sciences Alternatives Janux Therapeutics Alternatives Edgewise Therapeutics Alternatives Ardelyx Alternatives Harrow Alternatives ARS Pharmaceuticals Alternatives Schrodinger Alternatives Amphastar Pharmaceuticals Alternatives Vera Therapeutics Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAB) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access